GV and Celgene have returned for a $67m series C1 round in Armo Biosciences, which will use the cash to launch phase 2/3 clinical trials of its immunotherapy candidate.
US-based immuno-oncology treatment developer Armo Biosciences closed a $67m series C1 round on Tuesday with the support of GV, an investment arm of conglomerate Alphabet, and pharmaceutical firm Celgene.
The round was led by Qiming Venture Partners, with further participation from Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments, Kleiner Perkins Caufield & Byers (KPCB), OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments and unnamed funds advised by Clough Capital Partners.
GV and Celgene previously participated in a $50m series C…
